{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T22:10:37Z","timestamp":1779228637634,"version":"3.51.4"},"reference-count":143,"publisher":"MDPI AG","issue":"24","license":[{"start":{"date-parts":[[2020,12,16]],"date-time":"2020-12-16T00:00:00Z","timestamp":1608076800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Hypertrophic cardiomyopathy (HCM) and dilated cardiomyopathy (DCM) are the most prevalent forms of the chronic and progressive pathological condition known as cardiomyopathy. These diseases have different aetiologies; however, they share the feature of haemodynamic abnormalities, which is mainly due to dysfunction in the contractile proteins that make up the contractile unit known as the sarcomere. To date, pharmacological treatment options are not disease-specific and rather focus on managing the symptoms, without addressing the disease mechanism. Earliest attempts at improving cardiac contractility by modulating the sarcomere indirectly (inotropes) resulted in unwanted effects. In contrast, targeting the sarcomere directly, aided by high-throughput screening systems, could identify small molecules with a superior therapeutic value in cardiac muscle disorders. Herein, an extensive literature review of 21 small molecules directed to five different targets was conducted. A simple scoring system was created to assess the suitability of small molecules for therapy by evaluating them in eight different criteria. Most of the compounds failed due to lack of target specificity or poor physicochemical properties. Six compounds stood out, showing a potential therapeutic value in HCM, DCM or heart failure (HF). Omecamtiv Mecarbil and Danicamtiv (myosin activators), Mavacamten, CK-274 and MYK-581 (myosin inhibitors) and AMG 594 (Ca2+-sensitiser) are all small molecules that allosterically modulate troponin or myosin. Omecamtiv Mecarbil showed limited efficacy in phase III GALACTIC-HF trial, while, results from phase III EXPLORER-HCM trial were recently published, indicating that Mavacamten reduced left ventricular outflow tract (LVOT) obstruction and diastolic dysfunction and improved the health status of patients with HCM. A novel category of small molecules known as \u201crecouplers\u201d was reported to target a phenomenon termed uncoupling commonly found in familial cardiomyopathies but has not progressed beyond preclinical work. In conclusion, the contractile apparatus is a promising target for new drug development.<\/jats:p>","DOI":"10.3390\/ijms21249599","type":"journal-article","created":{"date-parts":[[2020,12,16]],"date-time":"2020-12-16T22:12:06Z","timestamp":1608156726000},"page":"9599","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":48,"title":["Small Molecules Acting on Myofilaments as Treatments for Heart and Skeletal Muscle Diseases"],"prefix":"10.3390","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5222-5576","authenticated-orcid":false,"given":"Khulud","family":"Alsulami","sequence":"first","affiliation":[{"name":"Imperial Centre for Translational and Experimental Medicine, Cardiovascular Division, National Heart and Lung Institute, Imperial College London, London W12 0NN, UK"},{"name":"National Centre for Pharmaceutical Technology, King Abdulaziz City for Science and Technology, Riyadh 11461, Saudi Arabia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6054-6070","authenticated-orcid":false,"given":"Steven","family":"Marston","sequence":"additional","affiliation":[{"name":"Imperial Centre for Translational and Experimental Medicine, Cardiovascular Division, National Heart and Lung Institute, Imperial College London, London W12 0NN, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2020,12,16]]},"reference":[{"key":"ref_1","unstructured":"World Health Organization (WHO) (2020, June 02). Cardiovascular Diseases. Available online: https:\/\/www.who.int\/health-topics\/cardiovascular-diseases\/."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1002\/ejhf.1461","article-title":"Heart failure in cardiomyopathies: A position paper from the Heart Failure Association of the European Society of Cardiology","volume":"21","author":"Polovina","year":"2019","journal-title":"Eur. J. Heart Fail."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1161\/CIRCULATIONAHA.106.174287","article-title":"Contemporary Definitions and Classification of the Cardiomyopathies","volume":"113","author":"Maron","year":"2006","journal-title":"Circulation"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1038\/nrcardio.2013.105","article-title":"Dilated cardiomyopathy: The complexity of a diverse genetic architecture","volume":"10","author":"Hershberger","year":"2013","journal-title":"Nat. Rev. Cardiol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1016\/S0140-6736(04)16358-7","article-title":"Hypertrophic cardiomyopathy","volume":"363","author":"Elliott","year":"2004","journal-title":"Lancet"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/S0168-9525(03)00081-7","article-title":"Hypertrophic cardiomyopathy: A paradigm for myocardial energy depletion","volume":"19","author":"Ashrafian","year":"2003","journal-title":"Trends Genet."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1093\/cvr\/cvv023","article-title":"Targets for therapy in sarcomeric cardiomyopathies","volume":"105","author":"Tardiff","year":"2015","journal-title":"Cardiovasc. Res."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s10974-014-9374-0","article-title":"Muscle dysfunction in hypertrophic cardiomyopathy: What is needed to move to translation?","volume":"35","author":"Poggesi","year":"2014","journal-title":"J. Muscle Res. Cell Motil."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/s10974-019-09519-9","article-title":"Nemaline myopathies: A current view","volume":"40","author":"Sewry","year":"2019","journal-title":"J. Muscle Res. Cell Motil."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1093\/cvr\/cvv181","article-title":"Uncoupling of myofilament Ca2+ sensitivity from troponin I phosphorylation by mutations can be reversed by epigallocatechin-3-gallate","volume":"108","author":"Papadaki","year":"2015","journal-title":"Cardiovasc. Res."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fphys.2014.00315","article-title":"Investigating the role of uncoupling of troponin I phosphorylation from changes in myofibrillar Ca2+-sensitivity in the pathogenesis of cardiomyopathy","volume":"5","author":"Messer","year":"2014","journal-title":"Front. Physiol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1016\/S0140-6736(17)31071-1","article-title":"Heart failure","volume":"390","author":"Metra","year":"2017","journal-title":"Lancet"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/nrcardio.2016.163","article-title":"Neurohormonal activation in heart failure with reduced ejection fraction","volume":"14","author":"Hartupee","year":"2016","journal-title":"Nat. Rev. Cardiol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1002\/ejhf.1557","article-title":"Why has positive inotropy failed in chronic heart failure? Lessons from prior inotrope trials","volume":"21","author":"Ahmad","year":"2019","journal-title":"Eur. J. Heart Fail."},{"key":"ref_15","first-page":"1064","article-title":"2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"21","author":"Ponikowski","year":"2019","journal-title":"Eur. J. Heart Fail."},{"key":"ref_16","first-page":"e282","article-title":"2016 ACC\/AHA\/HFSA focused update on new pharmacological therapy for heart failure: An update of the 2013 ACCF\/AHA guideline for the management of heart failure: A report of the American College of Cardiology\/American Heart Association Task Force on Clinic","volume":"134","author":"Yancy","year":"2016","journal-title":"Circulation"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.ijcard.2011.07.022","article-title":"Levosimendan: Molecular mechanisms and clinical implications: Consensus of experts on the mechanisms of action of levosimendan","volume":"159","author":"Papp","year":"2012","journal-title":"Int. J. Cardiol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.bbrc.2007.12.108","article-title":"Interaction of cardiac troponin with cardiotonic drugs: A structural perspective","volume":"369","author":"Li","year":"2008","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"9337","DOI":"10.1074\/jbc.M007484200","article-title":"Binding of Levosimendan, a Calcium Sensitizer, to Cardiac Troponin C","volume":"276","author":"Sorsa","year":"2001","journal-title":"J. Biol. Chem."},{"key":"ref_20","first-page":"277","article-title":"Mechanisms of the contractile effects of levosimendan in the mammalian heart","volume":"280","author":"Neumann","year":"1997","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1136\/hrt.76.3.223","article-title":"Effect of pimobendan on exercise capacity in patients with heart failure: Main results from the Pimobendan in Congestive Heart Failure (PICO) trial","volume":"76","author":"Lubsen","year":"1996","journal-title":"Heart"},{"key":"ref_22","unstructured":"AdisInsight (2020, September 08). Pimobendan\u2013AdisInsight. Available online: https:\/\/adisinsight.springer.com\/drugs\/800000190."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1097\/00005344-200102000-00008","article-title":"Increase in myofibrillar Ca2+ sensitivity induced by UD-CG 212 Cl, an active metabolite of pimobendan, in canine ventricular myocardium","volume":"37","author":"Takahashi","year":"2001","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"ref_24","first-page":"E1","article-title":"Pimobendan and its use in treating canine congestive heart failure","volume":"33","author":"Bowles","year":"2011","journal-title":"Compend. Contin. Educ. Vet."},{"key":"ref_25","unstructured":"AdisInsight (2020, July 15). Bepridil-AdisInsight. Available online: https:\/\/adisinsight.springer.com\/drugs\/800014884."},{"key":"ref_26","unstructured":"AdisInsight (2020, September 07). Senazodan-AdisInsight. Available online: https:\/\/adisinsight.springer.com\/drugs\/800000316."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1007\/s003920200032","article-title":"Effects of the Ca2+ sensitizers EMD 57033 and CGP 48506 on myocardial contractility and Ca2+ transients in human ventricular and atrial myocardium","volume":"91","author":"Brixius","year":"2001","journal-title":"Z. Kardiol."},{"key":"ref_28","first-page":"3893","article-title":"Myofilament Ca2+ sensitization causes susceptibility to cardiac arrhythmia in mice","volume":"118","author":"Baudenbacher","year":"2008","journal-title":"J. Clin. Investig."},{"key":"ref_29","unstructured":"AdisInsight (2020, July 24). AMG 594-AdisInsight. Available online: https:\/\/adisinsight.springer.com\/drugs\/800054180#:~:text=AMG."},{"key":"ref_30","unstructured":"Reagan, J.D., Hartman, J.J., Motani, A.S., Sutherland, W., Poppe, L., Hoagland, K., Rock, B., Lobenhofer, E., Nguyen, K.K., and Liu, Q. (2020, January 1\u20135). The novel myotrope, AMG 594, is a small-molecule cardiac troponin activator that increases cardiac contractility in vitro and in vivo. Proceedings of the Keystone Symposia on Molecular and Cellular Biology, Keystone, CO, USA. Available online: https:\/\/cytokinetics.com\/wp-content\/uploads\/2020\/03\/Keystone_HF_2020_AMG594.pdf."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.jchf.2012.12.004","article-title":"Effect of levosimendan on the short-term clinical course of patients with acutely decompensated heart failure","volume":"1","author":"Packer","year":"2013","journal-title":"JACC Heart Fail."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1053\/euhj.2001.3158","article-title":"Safety and efficacy of a novel calcium sensitizer, levosimendan, in patients with left ventricular failure due to an acute myocardial infarction: A randomized, placebo-controlled, double-blind study (RUSSLAN)","volume":"23","author":"Moiseyev","year":"2002","journal-title":"Eur. Heart J."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/S0140-6736(02)09455-2","article-title":"Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): A randomised double-blind trial","volume":"360","author":"Follath","year":"2002","journal-title":"Lancet"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1001\/jama.297.17.1883","article-title":"Levosimendan vs. dobutamine for patients with acute decompensated heart failure: The SURVIVE randomized trial","volume":"297","author":"Mebazaa","year":"2007","journal-title":"J. Am. Med. Assoc."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1126\/science.1200113","article-title":"Cardiac myosin activation: A potential therapeutic approach for systolic heart failure","volume":"331","author":"Malik","year":"2011","journal-title":"Science"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.yjmcc.2011.05.006","article-title":"Cardiac myosin activation part 1: From concept to clinic","volume":"51","author":"Malik","year":"2011","journal-title":"J. Mol. Cell Cardiol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1056\/NEJM199111213252103","article-title":"Effect of Oral Milrinone on Mortality in Severe Chronic Heart Failure","volume":"325","author":"Packer","year":"1991","journal-title":"N. Engl. J. Med."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/S0002-8703(99)70250-4","article-title":"Continuous intravenous dobutamine is associated with an increased risk of death in patients with advanced heart failure: Insights from the Flolan International Randomized Survival Trial (FIRST)","volume":"138","author":"Gattis","year":"1999","journal-title":"Am. Heart J."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1021\/ml100138q","article-title":"Discovery of omecamtiv mecarbil the first, selective, small molecule activator of cardiac myosin","volume":"1","author":"Morgan","year":"2010","journal-title":"ACS Med. Chem. Lett."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"3768","DOI":"10.1074\/jbc.M116.748780","article-title":"Omecamtiv mecarbil enhances the duty ratio of human \u03b2-cardiac myosin resulting in increased calcium sensitivity and slowed force development in cardiac muscle","volume":"292","author":"Swenson","year":"2017","journal-title":"J. Biol. Chem."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"4506","DOI":"10.1111\/bph.13235","article-title":"The novel cardiac myosin activator omecamtiv mecarbil increases the calcium sensitivity of force production in isolated cardiomyocytes and skeletal muscle fibres of the rat","volume":"172","author":"Nagy","year":"2015","journal-title":"Br. J. Pharmacol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1021\/bi5015166","article-title":"Omecamtiv Mecarbil Modulates the Kinetic and Motile Properties of Porcine \u03b2-Cardiac Myosin","volume":"54","author":"Liu","year":"2015","journal-title":"Biochemistry"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"3838","DOI":"10.1038\/s41467-018-06193-2","article-title":"Positive cardiac inotrope omecamtiv mecarbil activates muscle despite suppressing the myosin working stroke","volume":"9","author":"Woody","year":"2018","journal-title":"Nat. Commun."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1006\/jmbi.1998.1654","article-title":"The muscle thin filament as a classical cooperative\/allosteric regulatory system11Edited by P. E. Wright","volume":"277","author":"Lehrer","year":"1998","journal-title":"J. Mol. Biol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1161\/CIRCHEARTFAILURE.114.002152","article-title":"Myosin activator omecamtiv mecarbil increases myocardial oxygen consumption and impairs cardiac efficiency mediated by resting myosin ATPase activity","volume":"8","author":"Bakkehaug","year":"2015","journal-title":"Circ. Heart Fail."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1161\/CIRCHEARTFAILURE.115.002492","article-title":"Letter by Teerlink et al Regarding Article, \u201cMyosin Activator Omecamtiv Mecarbil Increases Myocardial Oxygen Consumption and Impairs Cardiac Efficiency Mediated by Resting Myosin ATPase Activity\u201d","volume":"8","author":"Teerlink","year":"2015","journal-title":"Circ. Heart Fail."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/S0140-6736(11)61219-1","article-title":"Dose-dependent augmentation of cardiac systolic function with the selective cardiac myosin activator, omecamtiv mecarbil: A first-in-man study","volume":"378","author":"Teerlink","year":"2011","journal-title":"Lancet"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1016\/j.jacc.2016.01.031","article-title":"Acute Treatment with Omecamtiv Mecarbil to Increase Contractility in Acute Heart Failure: The ATOMIC-AHF Study","volume":"67","author":"Teerlink","year":"2016","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1016\/j.jacc.2016.01.038","article-title":"Cardiac Myosin Activators for the Treatment of Heart Failure: Stop Now or Push Ahead?","volume":"67","author":"Starling","year":"2016","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_50","unstructured":"Teerlink, J.R., Diaz, R., Felker, G.M., McMurray, J.J.V.V., Metra, M., Solomon, S.D., Adams, K.F., Anand, I., Arias-Mendoza, A., and Biering-S\u00f8rensen, T. (2020). Cardiac Myosin Activation with Omecamtiv Mecarbil in Systolic Heart Failure. N. Engl. J. Med."},{"key":"ref_51","unstructured":"Fernandes, S., Oikonomopoulos, A., Jimenez-MacInnes, S.K., Aschar-Sobbi, R., Henze, M., Sumandea, M., Gan, Q.F., Anderson, R.L., and Del Rio, C.L. (2019). MYK-491, a Novel Small-Molecule Cardiac Myosin Activator Increases Cardiac Systolic Function and Preserves Mechanical Efficiency: Pre-Clinical in vivo and in vitro Evidence. Circulation, 140."},{"key":"ref_52","first-page":"423","article-title":"MYK-491, a Novel Cardiac Myosin Activator, Increases Cardiac Contractility in Healthy Volunteers","volume":"21","author":"Tamby","year":"2019","journal-title":"Eur. J. Heart Fail."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1002\/ejhf.1933","article-title":"Effects of danicamtiv, a novel cardiac myosin activator, in heart failure with reduced ejection fraction: Experimental data and clinical results from a phase 2a trial","volume":"22","author":"Voors","year":"2020","journal-title":"Eur. J. Heart Fail."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/S0140-6736(11)61126-4","article-title":"The effects of the cardiac myosin activator, omecamtiv mecarbil, on cardiac function in systolic heart failure: A double-blind, placebo-controlled, crossover, dose-ranging phase 2 trial","volume":"378","author":"Cleland","year":"2011","journal-title":"Lancet"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.jchf.2014.07.009","article-title":"Safety and Tolerability of Omecamtiv Mecarbil During Exercise in Patients with Ischemic Cardiomyopathy and Angina","volume":"3","author":"Greenberg","year":"2015","journal-title":"JACC Heart Fail."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"2895","DOI":"10.1016\/S0140-6736(16)32049-9","article-title":"Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure (COSMIC-HF): A phase 2, pharmacokinetic, randomised, placebo-controlled trial","volume":"388","author":"Teerlink","year":"2016","journal-title":"Lancet"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/S0735-1097(19)31299-9","article-title":"Effect of Omecamtiv Mecarbil in Patients With Atrial Fibrillation and Heart Failure With Reduced Ejection Fraction: Results From Cosmic-Hf","volume":"73","author":"Teerlink","year":"2019","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.jchf.2019.12.001","article-title":"Omecamtiv Mecarbil in Chronic Heart Failure With Reduced Ejection Fraction: Rationale and Design of GALACTIC-HF","volume":"8","author":"Teerlink","year":"2020","journal-title":"JACC Heart Fail."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/S0735-1097(20)31381-4","article-title":"Baseline characteristics from the cardiovascular outcomes trial of omecamtiv mecarbil (GALACTIC-HF)","volume":"75","author":"Teerlink","year":"2020","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_60","unstructured":"Lewis, G., B\u00f6hm, M., Cohen-Solal, A., Ezekowitz, J., Metra, M., Ponikowski, P., Teerlink, J., Voors, A., Whellan, D., and Legg, J. (2019, January 13\u201316). Multicenter Exercise Tolerance Evaluation of Omecamtiv Mecarbil Related to Increased Contractility in Heart Failure (METEORIC-HF). Proceedings of the Heart Failure Society of America 23rd Annual Scientific Meeting, Philadelphia, PA, USA. Available online: https:\/\/cytokinetics.com\/wp-content\/uploads\/2019\/09\/CY006-19-METEORIC-HFSA19-Study-Design-Poster_MT11_FINAL_UPLOAD.pdf."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"e01603","DOI":"10.7554\/eLife.01603","article-title":"Small molecule-mediated refolding and activation of myosin motor function","volume":"3","author":"Radke","year":"2014","journal-title":"eLife"},{"key":"ref_62","unstructured":"Amgen (2020, August 19). FDA Grants Fast Track Designation for Omecamtiv Mecarbil in Heart Failure. Available online: https:\/\/www.amgen.com\/media\/news-releases\/2020\/05\/fda-grants-fast-track-designation-for-omecamtiv-mecarbil-in-heart-failure\/."},{"key":"ref_63","unstructured":"Silber, E.N., and Katz, L.N. (2000). Therapeutic strategies for managing heart failure. Heart Failure: Pathophysiology, Molecular Biology, and Clinical Management, Lippincott Williams & Wilkins."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/nm.2618","article-title":"Activation of fast skeletal muscle troponin as a potential therapeutic approach for treating neuromuscular diseases","volume":"18","author":"Russell","year":"2012","journal-title":"Nat. Med."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s10974-019-09526-w","article-title":"Small molecule studies: The fourth wave of muscle research","volume":"40","author":"Marston","year":"2019","journal-title":"J. Muscle Res. Cell Motil."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1002\/mus.24239","article-title":"Tirasemtiv amplifies skeletal muscle response to nerve activation in humans","volume":"50","author":"Hansen","year":"2014","journal-title":"Muscle Nerve"},{"key":"ref_67","unstructured":"(2020, July 25). Cytokinetics. Cytokinetics Announces Orphan Drug Designation Granted to CK-2017357 for the Treatment of Amyotrophic Lateral Sclerosis | Cytokinetics, Inc. Available online: http:\/\/ir.cytokinetics.com\/news-releases\/news-release-details\/cytokinetics-announces-orphan-drug-designation-granted-ck."},{"key":"ref_68","unstructured":"(2020, July 24). Cytokinetics. Cytokinetics Announces Negative Results From VITALITY-ALS|Cytokinetics, Inc. Available online: http:\/\/ir.cytokinetics.com\/news-releases\/news-release-details\/cytokinetics-announces-negative-results-vitality-als."},{"key":"ref_69","unstructured":"AdisInsight (2020, July 26). Reldesemtiv-Astellas Pharma\/Cytokinetics-AdisInsight. Available online: https:\/\/adisinsight.springer.com\/drugs\/800037810."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1002\/mus.26017","article-title":"CK-2127107 amplifies skeletal muscle response to nerve activation in humans","volume":"57","author":"Andrews","year":"2018","journal-title":"Muscle Nerve"},{"key":"ref_71","unstructured":"(2020, July 27). CytoKinetics. Cytokinetics Announces Results of FORTITUDE-ALS, a Phase 2 Clinical Trial of Reldesemtiv in Patients With ALS, Presented at American Academy of Neurology Annual Meeting | Cytokinetics, Inc. Available online: http:\/\/ir.cytokinetics.com\/news-releases\/news-release-details\/cytokinetics-announces-results-fortitude-als-phase-2-clinical."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"4615","DOI":"10.1113\/JP278235","article-title":"Fast skeletal muscle troponin activator CK-2066260 increases fatigue resistance by reducing the energetic cost of muscle contraction","volume":"597","author":"Cheng","year":"2019","journal-title":"J. Physiol."},{"key":"ref_73","doi-asserted-by":"crossref","unstructured":"Lee, E.J., De Winter, J.M., Buck, D., Jasper, J.R., Malik, F.I., Labeit, S., Ottenheijm, C.A., and Granzier, H. (2013). Fast Skeletal Muscle Troponin Activation Increases Force of Mouse Fast Skeletal Muscle and Ameliorates Weakness Due to Nebulin-Deficiency. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0055861"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"13009","DOI":"10.1073\/pnas.1607536113","article-title":"Piperine\u2019s mitigation of obesity and diabetes can be explained by its up-regulation of the metabolic rate of resting muscle","volume":"113","author":"Nogara","year":"2016","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s12551-011-0044-9","article-title":"The role of the myosin ATPase activity in adaptive thermogenesis by skeletal muscle","volume":"3","author":"Cooke","year":"2011","journal-title":"Biophys. Rev."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"100027","DOI":"10.1016\/j.medidd.2020.100027","article-title":"Piperine: A comprehensive review of methods of isolation, purification, and biological properties","volume":"7","author":"Tiwari","year":"2020","journal-title":"Med. Drug Discov."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"426","DOI":"10.3109\/21678421.2016.1148169","article-title":"A randomized, placebo-controlled, double-blind phase IIb trial evaluating the safety and efficacy of tirasemtiv in patients with amyotrophic lateral sclerosis","volume":"17","author":"Shefner","year":"2016","journal-title":"Amyotroph. Later. Scler. Frontotempo. Degener."},{"key":"ref_78","unstructured":"(2020, July 04). Cytokinetics. Cytokinetics Announces Top-Line Results From BENEFIT-ALS|Cytokinetics, Inc. Available online: https:\/\/adisinsight.springer.com\/trials\/700221015."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1080\/21678421.2018.1426770","article-title":"VITALITY-ALS, a phase III trial of tirasemtiv, a selective fast skeletal muscle troponin activator, as a potential treatment for patients with amyotrophic lateral sclerosis: Study design and baseline characteristics","volume":"19","author":"Andrews","year":"2018","journal-title":"Amyotroph. Later. Scler. Frontotempo. Degener."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1080\/21678421.2019.1612922","article-title":"A phase III trial of Tirasemtiv as a potential treatment for amyotrophic lateral sclerosis","volume":"20","author":"Shefner","year":"2019","journal-title":"Amyotroph. Later. Scler. Frontotempo. Degener."},{"key":"ref_81","unstructured":"AdisInsight (2020, July 24). Tirasemtiv-Cytokinetics\u2013AdisInsight. Available online: https:\/\/adisinsight.springer.com\/drugs\/800030378."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1042\/BST20140324","article-title":"The myosin mesa and a possible unifying hypothesis for the molecular basis of human hypertrophic cardiomyopathy","volume":"43","author":"Spudich","year":"2015","journal-title":"Biochem. Soc. Trans."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1007\/s00424-019-02259-2","article-title":"Three perspectives on the molecular basis of hypercontractility caused by hypertrophic cardiomyopathy mutations","volume":"471","author":"Spudich","year":"2019","journal-title":"Pflug. Arch. Eur. J. Physiol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.tcm.2008.04.001","article-title":"Bioinformatics Assessment of \u03b2-Myosin Mutations Reveals Myosin\u2019s High Sensitivity to Mutations","volume":"18","author":"Buvoli","year":"2008","journal-title":"Trends Cardiovasc. Med."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1159\/000252808","article-title":"Cardiomyopathy: A systematic review of disease-causing mutations in myosin heavy chain 7 and their phenotypic manifestations","volume":"115","author":"Walsh","year":"2009","journal-title":"Cardiology"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1016\/j.bpj.2014.02.011","article-title":"Hypertrophic and Dilated Cardiomyopathy: Four Decades of Basic Research on Muscle Lead to Potential Therapeutic Approaches to These Devastating Genetic Diseases","volume":"106","author":"Spudich","year":"2014","journal-title":"Biophys. J."},{"key":"ref_87","first-page":"783","article-title":"2011 ACCF\/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: A report of the American College of cardiology foundation\/American heart association task force on practice guidelines","volume":"124","author":"Gersh","year":"2011","journal-title":"Circulation"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"2733","DOI":"10.1093\/eurheartj\/ehu284","article-title":"2014 ESC guidelines on diagnosis and management of hypertrophic cardiomyopathy: The task force for the diagnosis and management of hypertrophic cardiomyopathy of the European Society of Cardiology (ESC)","volume":"35","author":"Zamorano","year":"2014","journal-title":"Eur. Heart J."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1093\/ajcn\/74.2.227","article-title":"Catechin intake might explain the inverse relation between tea consumption and ischemic heart disease: The Zutphen Elderly Study","volume":"74","author":"Arts","year":"2001","journal-title":"Am. J. Clin. Nutr."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1161\/STROKEAHA.111.677500","article-title":"The impact of green tea and coffee consumption on the reduced risk of stroke incidence in japanese population: The Japan public health center-based study cohort","volume":"44","author":"Kokubo","year":"2013","journal-title":"Stroke"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1080\/07352689709701956","article-title":"Tea Chemistry","volume":"16","author":"Harbowy","year":"1997","journal-title":"Crit. Rev. Plant Sci."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1111\/j.1476-5381.2010.00942.x","article-title":"Biological actions of green tea catechins on cardiac troponin C","volume":"161","author":"Tadano","year":"2010","journal-title":"Br. J. Pharmacol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"125A","DOI":"10.1016\/j.bpj.2015.11.719","article-title":"Novel Potential Treatment of Familial Hypertrophic Cardiomyopathy with Analogues of the Green Tea Polyphenol Epigallocatechin-3-Gallate","volume":"110","author":"Robinson","year":"2016","journal-title":"Biophys. J."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1097\/00005344-200007000-00017","article-title":"Impact of \u03b2-adrenoceptor antagonists on myofilament calcium sensitivity of rabbit and human myocardium","volume":"36","author":"Zeitz","year":"2000","journal-title":"J. Cardiovas. Pharmacol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"558","DOI":"10.3389\/fphys.2017.00558","article-title":"Nebivolol desensitizes myofilaments of a hypertrophic cardiomyopathy mouse model","volume":"8","author":"Kresin","year":"2017","journal-title":"Front. Physiol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"612","DOI":"10.3389\/fphys.2020.00612","article-title":"Approaches to High-Throughput Analysis of Cardiomyocyte Contractility","volume":"11","author":"Wright","year":"2020","journal-title":"Front. Physiol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"243","DOI":"10.3389\/fphys.2018.00243","article-title":"Molecular defects in cardiac myofilament Ca2+-regulation due to cardiomyopathy-linked mutations can be reversed by small molecules binding to troponin","volume":"9","author":"Sheehan","year":"2018","journal-title":"Front. Physiol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1038\/513481a","article-title":"Chemical con artists foil drug discovery","volume":"513","author":"Baell","year":"2014","journal-title":"Nature"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1021\/cb500086e","article-title":"Phytochemicals perturb membranes and promiscuously alter protein function","volume":"9","author":"Thakur","year":"2014","journal-title":"ACS Chem. Biol."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1093\/cvr\/cvt071","article-title":"Familial dilated cardiomyopathy mutations uncouple troponin I phosphorylation from changes in myofibrillar Ca2+ sensitivity","volume":"99","author":"Memo","year":"2013","journal-title":"Cardiovasc. Res."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"2369","DOI":"10.1016\/j.bpj.2014.10.024","article-title":"The dilated cardiomyopathy-causing mutation ACTC E361G in cardiac muscle myofibrils specifically abolishes modulation of Ca2+ regulation by phosphorylation of troponin I","volume":"107","author":"Vikhorev","year":"2014","journal-title":"Biophys. J."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"H1936","DOI":"10.1152\/ajpheart.00327.2015","article-title":"A dilated cardiomyopathy mutation blunts adrenergic response and induces contractile dysfunction under chronic angiotensin II stress","volume":"309","author":"Wilkinson","year":"2015","journal-title":"Am. J. Physiol. Circ. Physiol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/0006-3002(55)90040-8","article-title":"A powerful reactivator of alkylphosphate-inhibited acetylcholinesterase","volume":"18","author":"Wilson","year":"1955","journal-title":"BBA Biochim. Biophys. Acta"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/ncb734","article-title":"A small-molecule inhibitor of skeletal muscle myosin II","volume":"4","author":"Cheung","year":"2002","journal-title":"Nat. Cell Biol."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1126\/science.1081412","article-title":"Dissecting temporal and spatial control of cytokinesis with a myosin II inhibitor","volume":"299","author":"Straight","year":"2003","journal-title":"Science"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.yjmcc.2013.09.004","article-title":"Preservation of cardiomyocytes from the adult heart","volume":"64","author":"Pointon","year":"2013","journal-title":"J. Mol. Cell Cardiol."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/j.tibs.2018.06.006","article-title":"Targeting Myosin by Blebbistatin Derivatives: Optimization and Pharmacological Potential","volume":"43","author":"Rauscher","year":"2018","journal-title":"Trends Biochem. Sci."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1016\/j.bpj.2014.07.075","article-title":"The myosin inhibitor blebbistatin stabilizes the super-relaxed state in skeletal muscle","volume":"107","author":"Wilson","year":"2014","journal-title":"Biophys. J."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"9410","DOI":"10.1021\/acs.jmedchem.8b00503","article-title":"Medicinal Chemistry and Use of Myosin II Inhibitor (S)-Blebbistatin and Its Derivatives","volume":"61","author":"Roman","year":"2018","journal-title":"J. Med. Chem."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1242\/jeb.125930","article-title":"Effects of hypertrophic and dilated cardiomyopathy mutations on power output by human \u03b2-cardiac myosin","volume":"219","author":"Spudich","year":"2016","journal-title":"J. Exp. Biol."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"3520","DOI":"10.1172\/JCI42028","article-title":"Cardiac fibrosis in mice with hypertrophic cardiomyopathy is mediated by non-myocyte proliferation and requires Tgf-\u03b2","volume":"120","author":"Tekakirikul","year":"2010","journal-title":"J. Clin. Investig."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1126\/science.aad3456","article-title":"Heart disease: A small-molecule inhibitor of sarcomere contractility suppresses hypertrophic cardiomyopathy in mice","volume":"351","author":"Green","year":"2016","journal-title":"Science"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"E8143","DOI":"10.1073\/pnas.1809540115","article-title":"Deciphering the super relaxed state of human \u03b2-cardiac myosin and the mode of action of mavacamten from myosin molecules to muscle fibers","volume":"115","author":"Anderson","year":"2018","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"E7486","DOI":"10.1073\/pnas.1720342115","article-title":"Mavacamten stabilizes an autoinhibited state of two-headed cardiac myosin","volume":"115","author":"Rohde","year":"2018","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"e0168407","DOI":"10.1371\/journal.pone.0168407","article-title":"A small molecule inhibitor of sarcomere contractility acutely relieves left ventricular outflow tract obstruction in feline hypertrophic cardiomyopathy","volume":"11","author":"Stern","year":"2016","journal-title":"PLoS ONE"},{"key":"ref_116","first-page":"A20593","article-title":"Abstract 20593: In vivo Cardiac Effects of Mavacamten (MYK-461): Evidence for Negative Inotropy and Improved Compliance","volume":"136","author":"Yukie","year":"2017","journal-title":"Circulation"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1080\/00498254.2018.1495856","article-title":"In vitro and in vivo pharmacokinetic characterization of mavacamten, a first-in-class small molecule allosteric modulator of beta cardiac myosin","volume":"49","author":"Grillo","year":"2019","journal-title":"Xenobiotica"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"741","DOI":"10.7326\/M18-3016","article-title":"Mavacamten treatment for obstructive hypertrophic cardiomyopathy a clinical trial","volume":"170","author":"Heitner","year":"2019","journal-title":"Ann. Intern. Med."},{"key":"ref_119","first-page":"A13962","article-title":"Precision Pharmacological Treatment for Obstructive Hypertrophic Cardiomyopathy With Mavacamten: One-Year Results From PIONEER-OLE","volume":"140","author":"Heitner","year":"2019","journal-title":"Circulation"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"2649","DOI":"10.1016\/j.jacc.2020.03.064","article-title":"Evaluation of Mavacamten in Symptomatic Patients With Nonobstructive Hypertrophic Cardiomyopathy","volume":"75","author":"Ho","year":"2020","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/S0140-6736(20)31792-X","article-title":"Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): A randomised, double-blind, placebo-controlled, phase 3 trial","volume":"396","author":"Olivotto","year":"2020","journal-title":"Lancet"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1161\/CIRCHEARTFAILURE.120.006853","article-title":"Study Design and Rationale of EXPLORER-HCM: Evaluation of Mavacamten in Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy","volume":"13","author":"Ho","year":"2020","journal-title":"Circ. Heart Fail."},{"key":"ref_123","first-page":"A14585","article-title":"Abstract 14585: Chronic Treatment With a Mavacamten-Like Myosin-Modulator (MYK-581) Blunts Disease Progression in a Mini-Pig Genetic Model of Non-Obstructed Hypertrophic Cardiomyopathy: In Vivo Evidence for Improved Relaxation and Functional Reserve","volume":"140","author":"Aprajita","year":"2019","journal-title":"Circulation"},{"key":"ref_124","unstructured":"(2020, August 22). MyoKardia Programs|MyoKardia. Available online: https:\/\/myokardia.com\/programs."},{"key":"ref_125","unstructured":"AdisInsight (2020, September 01). A Phase 1 Randomized, Placebo-Controlled, Single and Multiple-Ascending Dose Study of MYK-224 in Healthy Volunteers\u2014AdisInsight. Available online: https:\/\/adisinsight.springer.com\/trials\/700301316."},{"key":"ref_126","unstructured":"NIH (2020, August 30). Study Evaluating the Safety, Tolerability and Preliminary Pharmacokinetics and Pharmacodynamics of MYK-461-Full Text View\u2014ClinicalTrials.gov, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02329184."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"A644","DOI":"10.1016\/S0735-1097(18)31185-9","article-title":"Reduction in left ventricular outflow tract gradient with mavacamten (myk-461) in symptomatic obstructive hypertrophic cardiomyopathy patients (PIONEER-HCM)","volume":"71","author":"Jacoby","year":"2018","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"A17141","DOI":"10.1161\/circ.138.suppl_1.17141","article-title":"Mavacamten Improves Left Ventricular Relaxation and Compliance in Obstructive Hypertrophic Cardiomyopathy Through Direct Myosin Modulation","volume":"138","author":"Heitner","year":"2018","journal-title":"Circulation"},{"key":"ref_129","unstructured":"Ho, C.Y. (2020, January 15). Safety and Efficacy of Mavacamten in Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy: The MAVERICK-HCM Study. Proceedings of the American College of Cardiology (ACC)\/World Congress of Cardiology\u2019s (WCC) Virtual Scientific Sessions, Boston, MA, USA. Available online: https:\/\/www.emjreviews.com\/cardiology\/symposium\/safety-and-efficacy-of-mavacamten-in-patients-with-symptomatic-non-obstructive-hypertrophic-cardiomyopathy-the-maverick-hcm-study\/."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"A17067","DOI":"10.1161\/circ.138.suppl_1.17067","article-title":"Maverick-HCM: Phase 2 randomized, multi-center, double-blind, placebo-controlled concentration-guided study to evaluate mavacamten (MYK-461) in adults with symptomatic non-obstructive hypertrophic cardiomyopathy","volume":"138","author":"Heitner","year":"2018","journal-title":"Circulation"},{"key":"ref_131","unstructured":"NIH (2020, September 01). A Long-Term Safety Extension Study of Mavacamten in Adults Who Have Completed MAVERICK-HCM or EXPLORER-HCM\u2014Full Text View\u2014ClinicalTrials.gov, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03723655."},{"key":"ref_132","unstructured":"NIH (2020, September 01). A Study to Evaluate Mavacamten in Adults With Symptomatic Obstructive HCM Who Are Eligible for Septal Reduction Therapy\u2014Full Text View\u2014ClinicalTrials.gov, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04349072."},{"key":"ref_133","unstructured":"NIH (2020, August 31). A Single and Multiple Ascending Dose Study of CK-3773274 in Healthy Adult Subjects\u2014Full Text View\u2014ClinicalTrials.gov, Available online: https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT03767855?term=ck-3773274."},{"key":"ref_134","unstructured":"(2020, August 31). CytoKinetics. CytoKinetics Announces Data from Phase 1 Study of CK- 3773274 at the HFSA 23rd Annual Scientific Meeting. Available online: http:\/\/ir.cytokinetics.com\/news-releases\/news-release-details\/cytokinetics-announces-data-phase-1-study-ck-3773274-hfsa-23r."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"S79","DOI":"10.1016\/j.cardfail.2019.07.225","article-title":"A First in Human Study of the Selective Cardiac Myosin Inhibitor, CK-3773274","volume":"25","author":"Robertson","year":"2019","journal-title":"J. Card. Fail."},{"key":"ref_136","unstructured":"NIH (2020, August 31). REDWOOD-HCM: Randomized Evaluation of Dosing with CK-3773274 in Obstructive Outflow Disease in HCM\u2014Full Text View\u2014ClinicalTrials.gov, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04219826."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"596a","DOI":"10.1016\/j.bpj.2019.11.3225","article-title":"Characterization of the Cardiac Myosin Inhibitor CK-3773274: A Potential Therapeutic Approach for Hypertrophic Cardiomyopathy","volume":"118","author":"Hartman","year":"2020","journal-title":"Biophys. J."},{"key":"ref_138","first-page":"A332","article-title":"Pharmacologic Characterization of the Cardiac Myosin Inhibitor, CK-3773274: A Potential Therapeutic Approach for Hypertrophic Cardiomyopathy","volume":"125","author":"Hwee","year":"2019","journal-title":"Circ. Res."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"A615","DOI":"10.1161\/res.125.suppl_1.615","article-title":"The Cardiac Myosin Inhibitor, CK-3773274, Reduces Contractility in the R403q Mouse Model of Hypertrophic Cardiomyopathy","volume":"125","author":"Hwee","year":"2019","journal-title":"Circ. Res."},{"key":"ref_140","unstructured":"AdisInsight (2020, August 31). CK 274\u2014AdisInsight. Available online: https:\/\/adisinsight.springer.com\/drugs\/800053181."},{"key":"ref_141","unstructured":"(2020, August 29). Myokardia. MyoKardia Announces Receipt of Breakthrough Therapy Designation from FDA for Mavacamten for the Treatment of Symptomatic, Obstructive Hypertrophic Cardiomyopathy Nasdaq:MYOK. Available online: https:\/\/www.globenewswire.com\/news-release\/2020\/07\/23\/2066908\/0\/en\/MyoKardia-Announces-Receipt-of-Breakthrough-Therapy-Designation-from-FDA-for-Mavacamten-for-the-Treatment-of-Symptomatic-Obstructive-Hypertrophic-Cardiomyopathy.html."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1161\/CIRCULATIONAHA.107.702795","article-title":"Metabolic mechanisms in heart failure","volume":"116","author":"Ashrafian","year":"2007","journal-title":"Circulation"},{"key":"ref_143","unstructured":"(2020, December 10). MyoKardia. MyoKardia Announces Positive Topline Data from its Phase 2 MAVERICK-HCM Clinical Trial of Mavacamten|Bristol-Myers Squibb. Available online: http:\/\/investors.myokardia.com\/news-releases\/news-release-details\/myokardia-announces-positive-topline-data-its-phase-2-maverick."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/21\/24\/9599\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T10:46:05Z","timestamp":1760179565000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/21\/24\/9599"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,16]]},"references-count":143,"journal-issue":{"issue":"24","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["ijms21249599"],"URL":"https:\/\/doi.org\/10.3390\/ijms21249599","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12,16]]}}}